Skip to main content
ANG Lifesciences India Limited logo

ANG Lifesciences India Limited — Investor Relations & Filings

Ticker · 540694 ISIN · INE236W01016 LEI · 3358002NI72T6WPZB386 BSE.NS Manufacturing
Open in API
Filings indexed 5 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country IN India
Listing BSE.NS 540694

About ANG Lifesciences India Limited

http://anglifesciences.com

ANG Lifesciences India Limited specializes in the development, manufacturing, and marketing of finished dosage formulations. The company primarily focuses on sterile dry powder injections, including beta-lactam and non-beta-lactam categories such as cephalosporins, carbapenems, and penicillins. Its product portfolio also encompasses liquid injectables, vials, and ampoules across various therapeutic segments, including anti-infectives and critical care. Utilizing advanced manufacturing facilities that adhere to stringent quality standards, the company produces a diverse range of generic medicines. Its operations are characterized by a focus on research-driven production processes and the delivery of therapeutic solutions intended for intensive care and hospital settings.

Recent filings

Filing Released Lang Actions
Newspaper Publication of Audited Financial Results for the quarter and year ended March 31, 2026.
Regulatory Filings Classification · 72% confidence The document is a SEBI Listing Obligations disclosure (Regulation 30 & 47) letter to BSE enclosing a newspaper advertisement of audited financial results. It is not the full annual or interim report itself, nor a management discussion/analysis, but a regulatory announcement of the results. It does include summary financial data in tabular form for statutory publication, yet the primary purpose is to file the newspaper advertisement under listing rules. This fits the “Regulatory Filings” (RNS) category as a generic compliance announcement that does not fall under dedicated report or earnings‐release headings.
2026-06-05 English
Audited Results 31.03.2026
Interim / Quarterly Report Classification · 85% confidence The document is a regulatory filing under SEBI LODR reporting the audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026, including full financial statements (assets & liabilities, profit & loss, cash flows) and the auditors’ report. It is not the company’s full annual report (10-K) with MD&A and governance sections, nor a brief earnings release; it is a comprehensive periodic financial report for a shorter period (quarter and year-end results). Therefore, it fits the Interim/Quarterly Report category. FY 2026
2026-05-30 English
Audited Financial Results for the quarter and year ended 31st March, 2026
Interim / Quarterly Report Classification · 90% confidence The document is the Board meeting outcome under SEBI LODR Reg 30 & 33, enclosing the Audited Standalone and Consolidated Financial Results for quarter and year ended 31 March 2026, with complete financial statements (Statement of Assets & Liabilities, P&L, Cash Flows, etc.). This goes beyond a mere earnings release (high‐level highlights) and contains substantive financial data, fitting the definition of an Interim/Quarterly Report rather than a full Annual Report or simple regulatory announcement. Therefore it should be classified as an Interim / Quarterly Report (IR). FY 2026
2026-05-30 English
Annual Secretarial Compliance Report 31.03.2026.
Regulatory Filings Classification · 85% confidence The document is a Secretarial Compliance Report issued by a practicing company secretary certifying the listed entity’s adherence to SEBI Listing Obligations and Disclosure Requirements. It is an officer certification/attestation rather than a full financial report or management discussion. Under the “Certification Rule,” such compliance certificates and regulatory attestations should be classified as Regulatory Filings (RNS).
2026-05-29 English
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Standalone & Consolidated ....
Regulatory Filings Classification · 87% confidence The document is a Notice of Board Meeting under SEBI Listing Regulations, informing BSE of the scheduled board meeting date to approve financial results. It is a compliance announcement rather than the actual financial report or an AGM notice, and does not announce any director change. This falls under general regulatory filings (miscellaneous listing compliance) rather than a specific report or management change category. Hence, it is classified as RNS.
2026-05-22 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.